Vitamin E and neurodegenerative diseases

Molecular Aspects of Medicine

Volumn 28, Issue 5-6, 2007, Pages 591-606

  Ricciarelli, Roberta ^a   Argellati, Francesca ^a   Pronzato, Maria A ^a   Domenicotti, Cinzia ^a  

^a Department of Experimental Medicine ^*  (Italy)

Author keywords

AD; ALS; AVED; Neurodegenerative disease; Oxidative stress; PD; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ASCORBIC ACID; DONEPEZIL; SELEGILINE;

ALPHA TOCOPHEROL DEFICIENCY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ATAXIA; CLINICAL TRIAL; DEGENERATIVE DISEASE; DRUG MEGADOSE; HUMAN; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; VITAMIN SUPPLEMENTATION;

EID: 35448981428     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2007.01.004     Document Type: Review

References (111)

1. Abou-Sleiman P.M., Muqit M.M., and Wood N.W. Expanding insights of mitochondrial dysfunction in Parkinson's disease. Nat. Rev. Neurosci. 7 (2006) 207-219
2. Adams Jr. J.D., and Wang B. Vitamin E uptake into the brain and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine toxicity. J. Cereb. Blood Flow Metab. 14 (1994) 362-363
3. Alam Z.I., et al. A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69 (1997) 1326-1329
4. Alonso A.C., Grundke-Iqbal I., and Iqbal K. Alzheimer's disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med. 2 (1996) 783-787
5. Ascherio A., et al. Vitamin E intake and risk of amyotrophic lateral sclerosis. Ann. Neurol. 57 (2005) 104-110
6. Beal M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38 (1995) 357-366
7. Behl C., Davis J.B., Lesley R., and Schubert D. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 77 (1994) 817-827
8. Ben Hamida C., et al. Localization of Friedreich ataxia phenotype with selective vitamin E deficiency to chromosome 8q by homozygosity mapping. Nat. Genet. 5 (1993) 195-200
9. Blake C.I., Spitz E., Leehey M., Hoffer B.J., and Boyson S.J. Platelet mitochondrial respiratory chain function in Parkinson's disease. Mov. Disord. 12 (1997) 3-8
10. Bossy-Wetzel E., Schwarzenbacher R., and Lipton S.A. Molecular pathways to neurodegeneration. Nat. Med. 10 Suppl. (2004) S2-S9
11. Bruijn L.I., et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281 (1998) 1851-1854
12. Burton G.W., Joyce A., and Ingold K.U. Is vitamin E the only lipid-soluble, chain-breaking antioxidant in human blood plasma and erythrocyte membranes?. Arch. Biochem. Biophys. 221 (1983) 281-290
13. Butterfield D.A., Castegna A., Drake J., Scapagnini G., and Calabrese V. Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr. Neurosci. 5 (2002) 229-239
14. Canevari L., Abramov A.Y., and Duchen M.R. Toxicity of amyloid beta peptide: tales of calcium, mitochondria, and oxidative stress. Neurochem. Res. 29 (2004) 637-650
15. Castellani R., Smith M.A., Richey P.L., and Perry G. Glycoxidation and oxidative stress in Parkinson disease and diffuse Lewy body disease. Brain Res. 737 (1996) 195-200
16. Cavalier L., et al. Ataxia with isolated vitamin E deficiency: heterogeneity of mutations and phenotypic variability in a large number of families. Am. J. Hum. Genet. 62 (1998) 301-310
17. Chi D.S., Gong L., Daigneault E.A., and Kostrzewa R.M. Effects of MPTP and vitamin E treatments on immune function in mice. Int. J. Immunopharmacol. 14 (1992) 739-746
18. Clement A.M., et al. Wild-type nonneuronal cells extend survival of SOD1 mutant motor neurons in ALS mice. Science 302 (2003) 113-117
19. Coyle J.T., and Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 262 (1993) 689-695
20. Curtain C.C., et al. Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J. Biol. Chem. 276 (2001) 20466-20473
21. Desnuelle C., Dib M., Garrel C., and Favier A. A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph. Lateral Scler. Other Motor Neuron Disord. 2 (2001) 9-18
22. Dexter D.T., et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52 (1989) 381-389
23. Dexter D.T., et al. Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra: an HPLC and ESR study. Mov. Disord. 9 (1994) 92-97
24. Dupuis L., et al. Mitochondria in amyotrophic lateral sclerosis: a trigger and a target. Neurodegeneration Dis. 1 (2004) 245-254
25. Dyrks T., Dyrks E., Masters C.L., and Beyreuther K. Amyloidogenicity of rodent and human beta A4 sequences. FEBS Lett. 324 (1993) 231-236
26. Engelhart M.J., et al. Dietary intake of antioxidants and risk of Alzheimer disease. Jama 287 (2002) 3223-3229
27. Etminan M., Gill S.S., and Samii A. Intake of vitamin E, vitamin C, and carotenoids and the risk of Parkinson's disease: a meta-analysis. Lancet Neurol. 4 (2005) 362-365
28. Evans P.H. Free radicals in brain metabolism and pathology. Br. Med. Bull. 49 (1993) 577-587
29. Fahn S. A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease. Ann. Neurol. 32 Suppl. (1992) S128-S132
30. Fahn S., and Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Ann. Neurol. 32 (1992) 804-812
31. Floyd R.A., and Hensley K. Oxidative stress in brain aging. Implications for therapeutics of neurodegenerative diseases. Neurobiol. Aging 23 (2002) 795-807
32. Garcia-Alloza M., Dodwell S.A., Meyer-Luehmann M., Hyman B.T., and Bacskai B.J. Plaque-derived oxidative stress mediates distorted neurite trajectories in the Alzheimer mouse model. J. Neuropathol. Exp. Neurol. 65 (2006) 1082-1089
33. Gong L., Daigneault E.A., Acuff R.V., and Kostrzewa R.M. Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity. Neuroreport 2 (1991) 544-546
34. Gotoda T., et al. Adult-onset spinocerebellar dysfunction caused by a mutation in the gene for the alpha-tocopherol-transfer protein. N. Engl. J. Med. 333 (1995) 1313-1318
35. Graf M., et al. High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J. Neural Transm. 112 (2005) 649-660
36. Grundke-Iqbal I., et al. Microtubule-associated protein tau. A component of Alzheimer paired helical filaments. J. Biol. Chem. 261 (1986) 6084-6089
37. Gurney M.E., et al. Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann. Neurol. 39 (1996) 147-157
38. Halliwell B. Oxygen radicals as key mediators in neurological disease: fact or fiction?. Ann. Neurol. 32 Suppl. (1992) S10-S15
39. Halliwell B. Antioxidant defence mechanisms: from the beginning to the end (of the beginning). Free Radic. Res. 31 (1999) 261-272
40. Hensley K., et al. Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation. J. Neurochem. 65 (1995) 2146-2156
41. Ingold K.U., et al. Vitamin E remains the major lipid-soluble, chain-breaking antioxidant in human plasma even in individuals suffering severe vitamin E deficiency. Arch. Biochem. Biophys. 259 (1987) 224-225
42. Jenner P. Oxidative stress as a cause of Parkinson's disease. Acta Neurol. Scand. Suppl. 136 (1991) 6-15
43. Jenner P. Oxidative damage in neurodegenerative disease. Lancet 344 (1994) 796-798
44. Jenner P. Oxidative stress in Parkinson's disease. Ann. Neurol. 53 Suppl. 3 (2003) S26-S36 discussion S36-S38
45. Kayden H.J., and Traber M.G. Absorption, lipoprotein transport, and regulation of plasma concentrations of vitamin E in humans. J. Lipid Res. 34 (1993) 343-358
46. Kikuchi A., et al. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol. Dis. 9 (2002) 244-248
47. Knight J.A. Reactive oxygen species and the neurodegenerative disorders. Ann. Clin. Lab. Sci. 27 (1997) 11-25
48. Koenig M., and Mandel J.L. Deciphering the cause of Friedreich ataxia. Curr. Opin. Neurobiol. 7 (1997) 689-694
49. Law A., Gauthier S., and Quirion R. Say NO to Alzheimer's disease: the putative links between nitric oxide and dementia of the Alzheimer's type. Brain Res. Brain Res. Rev. 35 (2001) 73-96
50. Lee H.S., Park C.W., and Kim Y.S. MPP(+) increases the vulnerability to oxidative stress rather than directly mediating oxidative damage in human neuroblastoma cells. Exp. Neurol. 165 (2000) 164-171
51. Lei S.Z., et al. Effect of nitric oxide production on the redox modulatory site of the NMDA receptor-channel complex. Neuron 8 (1992) 1087-1099
52. Lenaz G., et al. Role of mitochondria in oxidative stress and aging. Ann. N.Y. Acad. Sci. 959 (2002) 199-213
53. Li J., Billiar T.R., Talanian R.V., and Kim Y.M. Nitric oxide reversibly inhibits seven members of the caspase family via S-nitrosylation. Biochem. Biophys. Res. Commun. 240 (1997) 419-424
54. Longnecker M.P., et al. Dietary intake of calcium, magnesium and antioxidants in relation to risk of amyotrophic lateral sclerosis. Neuroepidemiology 19 (2000) 210-216
55. Longo F.M., and Massa S.M. Neurotrophin-based strategies for neuroprotection. J. Alzheimers Dis. 6 (2004) S13-S17
56. Lovell M.A., Ehmann W.D., Butler S.M., and Markesbery W.R. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45 (1995) 1594-1601
57. Mariotti C., et al. Ataxia with isolated vitamin E deficiency: neurological phenotype, clinical follow-up and novel mutations in TTPA gene in Italian families. Neurol. Sci. 25 (2004) 130-137
58. Mark M.H. Lumping and splitting the Parkinson Plus syndromes: dementia with Lewy bodies, multiple system atrophy, progressive supranuclear palsy, and cortical-basal ganglionic degeneration. Neurol. Clin. 19 (2001) 607-627
59. Markesbery W.R. Oxidative stress hypothesis in Alzheimer's disease. Free Radic. Biol. Med. 23 (1997) 134-147
60. Markesbery W.R., and Carney J.M. Oxidative alterations in Alzheimer's disease. Brain Pathol. 9 (1999) 133-146
61. Markesbery W.R., and Lovell M.A. Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease. Neurobiol. Aging 19 (1998) 33-36
62. Martin A., Janigian D., Shukitt-Hale B., Prior R.L., and Joseph J.A. Effect of vitamin E intake on levels of vitamins E and C in the central nervous system and peripheral tissues: implications for health recommendations. Brain Res. 845 (1999) 50-59
63. Mattson M.P. Pathways towards and away from Alzheimer's disease. Nature 430 (2004) 631-639
64. McGeer P.L., McGeer E.G., and Yasojima K. Alzheimer disease and neuroinflammation. J. Neural Transm. Suppl. 59 (2000) 53-57
65. Mecocci P., et al. Oxidative damage to DNA in lymphocytes from AD patients. Neurology 51 (1998) 1014-1017
66. Mecocci P., MacGarvey U., and Beal M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol. 36 (1994) 747-751
67. Migliore L., et al. Oxidative damage and cytogenetic analysis in leukocytes of Parkinson's disease patients. Neurology 58 (2002) 1809-1815
68. Montiel T., Quiroz-Baez R., Massieu L., and Arias C. Role of oxidative stress on beta-amyloid neurotoxicity elicited during impairment of energy metabolism in the hippocampus: protection by antioxidants. Exp. Neurol. 200 (2006) 496-508
69. Morris M.C., Evans D.A., Bienias J.L., Tangney C.C., and Wilson R.S. Vitamin E and cognitive decline in older persons. Arch. Neurol. 59 (2002) 1125-1132
70. Nelson L.M., Matkin C., Longstreth Jr. W.T., and McGuire V. Population-based case-control study of amyotrophic lateral sclerosis in western Washington State. II. Diet. Am. J. Epidemiol. 151 (2000) 164-173
71. Nishida Y., et al. Deletion of vitamin E enhances phenotype of Alzheimer disease model mouse. Biochem. Biophys. Res. Commun. 350 (2006) 530-536
72. Nunomura A., et al. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol. 60 (2001) 759-767
73. Odunze I.N., Klaidman L.K., and Adams Jr. J.D. MPTP toxicity in the mouse brain and vitamin E. Neurosci. Lett. 108 (1990) 346-349
74. Parkinson Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Arch. Neurol. 46 (1989) 1052-1060
75. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N. Engl. J. Med. 328 (1993) 176-183
76. Penn A.M., et al. Generalized mitochondrial dysfunction in Parkinson's disease detected by magnetic resonance spectroscopy of muscle. Neurology 45 (1995) 2097-2099
77. Perkins A.J., et al. Association of antioxidants with memory in a multiethnic elderly sample using the Third National Health and Nutrition Examination Survey. Am. J. Epidemiol. 150 (1999) 37-44
78. Perry T.L., et al. Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse. Neurosci. Lett. 60 (1985) 109-114
79. Petersen R.C., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 352 (2005) 2379-2388
80. Pham D.Q., and Plakogiannis R. Vitamin E supplementation in cardiovascular disease and cancer prevention: Part 1. Ann. Pharmacother. 39 (2005) 1870-1878
81. Ponten, S.C., Kwee, M.L., Wolters, E.C., Zijlmans, J.C., 2006. First case of ataxia with isolated vitamin E deficiency in the Netherlands. Parkinsonism Relat. Disord., in press.
82. Puglielli L., Tanzi R.E., and Kovacs D.M. Alzheimer's disease: the cholesterol connection. Nat. Neurosci. 6 (2003) 345-351
83. Ren Y.R., et al. Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain. J. Neurochem. 98 (2006) 1810-1816
84. Ricciarelli R., Zingg J.M., and Azzi A. Vitamin E: protective role of a Janus molecule. Faseb J. 15 (2001) 2314-2325
85. Rinaldi P., et al. Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease. Neurobiol. Aging 24 (2003) 915-919
86. Ripps M.E., Huntley G.W., Hof P.R., Morrison J.H., and Gordon J.W. Transgenic mice expressing an altered murine superoxide dismutase gene provide an animal model of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA 92 (1995) 689-693
87. Rosen D.R., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362 (1993) 59-62
88. Rota C., rimbach G., Minihane A.M., Stoecklin E., and Barella L. Dietary vitamin E modulates differential gene expression in the rat hippocampus: potential implication for its neuroprotective properties. Nutr. Neurosci. 8 (2005) 21-29
89. Samii A., Nutt J.G., and Ransom B.R. Parkinson's disease. Lancet 363 (2004) 1783-1793
90. Sano M., et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N. Engl. J. Med. 336 (1997) 1216-1222
91. Savitt J.M., Dawson V.L., and Dawson T.M. Diagnosis and treatment of Parkinson disease: molecules to medicine. J. Clin. Invest. 116 (2006) 1744-1754
92. Selkoe D.J. Defining molecular targets to prevent Alzheimer disease. Arch. Neurol. 62 (2005) 192-195
93. Smith C.D., et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc. Natl. Acad. Sci. USA 88 (1991) 10540-10543
94. Smith M.A., Harris P.L., Sayre L.M., and Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA 94 (1997) 9866-9868
95. Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K., and Perry G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta 1502 (2000) 139-144
96. Stolzing A., Widmer R., Jung T., Voss P., and Grune T. Tocopherol-mediated modulation of age-related changes in microglial cells: Turnover of extracellular oxidated protein material. Free Radic. Biol. Med. 40 (2006) 2126-2135
97. Subbarao K.V., Richardson J.S., and Ang L.C. Autopsy samples of Alzheimer's cortex show increased peroxidation in vitro. J. Neurochem. 55 (1990) 342-345
98. Sung S., et al. Early vitamin E supplementation in young but not aged mice reduces Abeta levels and amyloid deposition in a transgenic model of Alzheimer's disease. Faseb J. 18 (2004) 323-325
99. Tanzi R.E., and Bertram L. New frontiers in Alzheimer's disease genetics. Neuron 32 (2001) 181-184
100. Traber M.G., et al. Discrimination between forms of vitamin E by humans with and without genetic abnormalities of lipoprotein metabolism. J. Lipid Res. 33 (1992) 1171-1182
101. Troncoso J.C., Costello A., Watson Jr. A.L., and Johnson G.V. In vitro polymerization of oxidized tau into filaments. Brain Res. 613 (1993) 313-316
102. Weber C.A., and Ernst M.E. Antioxidants, supplements, and Parkinson's disease. Ann. Pharmacother. 40 (2006) 935-938
103. Wong P.C., et al. An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 14 (1995) 1105-1116
104. Yatin S.M., Aksenov M., and Butterfield D.A. The antioxidant vitamin E modulates amyloid beta-peptide-induced creatine kinase activity inhibition and increased protein oxidation: implications for the free radical hypothesis of Alzheimer's disease. Neurochem. Res. 24 (1999) 427-435
105. Yokota T., et al. Friedreich-like ataxia with retinitis pigmentosa caused by the His101Gln mutation of the alpha-tocopherol transfer protein gene. Ann. Neurol. 41 (1997) 826-832
106. Yokota T., et al. Postmortem study of ataxia with retinitis pigmentosa by mutation of the alpha-tocopherol transfer protein gene. J. Neurol. Neurosurg. Psychiatr. 68 (2000) 521-525
107. Yokota T., et al. Delayed-onset ataxia in mice lacking alpha -tocopherol transfer protein: model for neuronal degeneration caused by chronic oxidative stress. Proc. Natl. Acad. Sci. USA 98 (2001) 15185-15190
108. Zarkovic N., et al. Anticancer and antioxidative effects of micronized zeolite clinoptilolite. Anticancer Res. 23 (2003) 1589-1595
109. Zeevalk, G.D., Manzino, L., Sonsalla, P.K., Bernard, L.P., 2006. Characterization of intracellular elevation of glutathione (GSH) with glutathione monoethyl ester and GSH in brain and neuronal cultures: relevance to Parkinson's disease. Exp. Neurol., in press.
110. Zhang S.M., et al. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59 (2002) 1161-1169
111. Zhu X., Raina A.K., Perry G., and Smith M.A. Alzheimer's disease: the two-hit hypothesis. Lancet Neurol. 3 (2004) 219-226